Cargando…

A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei

BACKGROUND: Safe and effective vaccines are crucial for the control and eventual elimination of malaria. Novel approaches to optimize and improve vaccine efficacy are urgently required. Nanoparticle-based delivery platforms are considered potent and powerful tools for vaccine development. METHODS: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Guixiang, Min, Hui, Yu, Xinxin, Liu, Fei, Cui, Liwang, Cao, Yaming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626823/
https://www.ncbi.nlm.nih.gov/pubmed/37932796
http://dx.doi.org/10.1186/s13071-023-06020-8
_version_ 1785131420213051392
author Yao, Guixiang
Min, Hui
Yu, Xinxin
Liu, Fei
Cui, Liwang
Cao, Yaming
author_facet Yao, Guixiang
Min, Hui
Yu, Xinxin
Liu, Fei
Cui, Liwang
Cao, Yaming
author_sort Yao, Guixiang
collection PubMed
description BACKGROUND: Safe and effective vaccines are crucial for the control and eventual elimination of malaria. Novel approaches to optimize and improve vaccine efficacy are urgently required. Nanoparticle-based delivery platforms are considered potent and powerful tools for vaccine development. METHODS: In this study, we developed a transmission-blocking vaccine against malaria by conjugating the ookinete surface antigen PSOP25 to the Acinetobacter phage coat protein AP205, forming virus-like particles (VLPs) using the SpyTag/SpyCatcher adaptor system. The combination of AP205-2*SpyTag with PSOP25-SpyCatcher resulted in the formation of AP205-PSOP25 complexes (VLP-PSOP25). The antibody titers and avidity of serum from each immunization group were assessed by ELISA. Western blot and IFA were performed to confirm the specific reactivity of the elicit antisera to the native PSOP25 in Plasmodium berghei ookinetes. Both in vitro and in vivo assays were conducted to evaluate the transmission-blocking activity of VLP-PSOP25 vaccine. RESULTS: Immunization of mice with VLP-PSOP25 could induced higher levels of high-affinity antibodies than the recombinant PSOP25 (rPSOP25) alone or mixtures of untagged AP205 and rPSOP25 but was comparable to rPSOP25 formulated with alum. Additionally, the VLP-PSOP25 vaccine enhanced Th1-type immune response with remarkably increased levels of IgG2a subclass. The antiserum generated by VLP-PSOP25 specifically recognizes the native PSOP25 antigen in P. berghei ookinetes. Importantly, antisera generated by inoculation with the VLP-PSOP25 could inhibit ookinete development in vitro and reduce the prevalence of infected mosquitoes or oocyst intensity in direct mosquito feeding assays. CONCLUSIONS: Antisera elicited by immunization with the VLP-PSOP25 vaccine confer moderate transmission-reducing activity and transmission-blocking activity. Our results support the utilization of the AP205-SpyTag/SpyCatcher platform for next-generation TBVs development. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-023-06020-8.
format Online
Article
Text
id pubmed-10626823
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106268232023-11-07 A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei Yao, Guixiang Min, Hui Yu, Xinxin Liu, Fei Cui, Liwang Cao, Yaming Parasit Vectors Research BACKGROUND: Safe and effective vaccines are crucial for the control and eventual elimination of malaria. Novel approaches to optimize and improve vaccine efficacy are urgently required. Nanoparticle-based delivery platforms are considered potent and powerful tools for vaccine development. METHODS: In this study, we developed a transmission-blocking vaccine against malaria by conjugating the ookinete surface antigen PSOP25 to the Acinetobacter phage coat protein AP205, forming virus-like particles (VLPs) using the SpyTag/SpyCatcher adaptor system. The combination of AP205-2*SpyTag with PSOP25-SpyCatcher resulted in the formation of AP205-PSOP25 complexes (VLP-PSOP25). The antibody titers and avidity of serum from each immunization group were assessed by ELISA. Western blot and IFA were performed to confirm the specific reactivity of the elicit antisera to the native PSOP25 in Plasmodium berghei ookinetes. Both in vitro and in vivo assays were conducted to evaluate the transmission-blocking activity of VLP-PSOP25 vaccine. RESULTS: Immunization of mice with VLP-PSOP25 could induced higher levels of high-affinity antibodies than the recombinant PSOP25 (rPSOP25) alone or mixtures of untagged AP205 and rPSOP25 but was comparable to rPSOP25 formulated with alum. Additionally, the VLP-PSOP25 vaccine enhanced Th1-type immune response with remarkably increased levels of IgG2a subclass. The antiserum generated by VLP-PSOP25 specifically recognizes the native PSOP25 antigen in P. berghei ookinetes. Importantly, antisera generated by inoculation with the VLP-PSOP25 could inhibit ookinete development in vitro and reduce the prevalence of infected mosquitoes or oocyst intensity in direct mosquito feeding assays. CONCLUSIONS: Antisera elicited by immunization with the VLP-PSOP25 vaccine confer moderate transmission-reducing activity and transmission-blocking activity. Our results support the utilization of the AP205-SpyTag/SpyCatcher platform for next-generation TBVs development. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-023-06020-8. BioMed Central 2023-11-06 /pmc/articles/PMC10626823/ /pubmed/37932796 http://dx.doi.org/10.1186/s13071-023-06020-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yao, Guixiang
Min, Hui
Yu, Xinxin
Liu, Fei
Cui, Liwang
Cao, Yaming
A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei
title A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei
title_full A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei
title_fullStr A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei
title_full_unstemmed A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei
title_short A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei
title_sort nanoparticle vaccine displaying the ookinete psop25 antigen elicits transmission-blocking antibody response against plasmodium berghei
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626823/
https://www.ncbi.nlm.nih.gov/pubmed/37932796
http://dx.doi.org/10.1186/s13071-023-06020-8
work_keys_str_mv AT yaoguixiang ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT minhui ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT yuxinxin ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT liufei ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT cuiliwang ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT caoyaming ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT yaoguixiang nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT minhui nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT yuxinxin nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT liufei nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT cuiliwang nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei
AT caoyaming nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei